Pathogenesis and Treatment of NUT-Midline Carcinoma
Pathogenesis and Treatment of NUT-Midline Carcinoma
批准号:
9926545
负责人:
Christopher A French
金额:
$23.21万
依托单位国家:
美国
项目类别:
财政年份:
2007
资助国家:
美国
项目状态:
已结题
起止时间:
2007-08-30 至 2023-05-31
关键词:
BindingBromodomainCarcinomaCellsChromatinChromatin LoopComplexDNADevelopmentDifferentiated GeneDiseaseDose-LimitingEP300 geneEnhancersEnrollmentGenesGenetic TranscriptionGoalsGrowthHistone DeacetylaseHistonesLysineMalignant Epithelial CellMalignant NeoplasmsModelingMolecular ConformationNutsOncogenesOncoproteinsPathogenesisPathologicPatientsPrincipal InvestigatorProteinsRecruitment ActivityRoleSeedsSolid NeoplasmSquamous cell carcinomaStructure-Activity RelationshipTestingTransferaseTreatment EfficacyUp-Regulationcell typechromatin remodelinginhibitor/antagonistmimeticsnovelnovel therapeuticspreventprogramsprotein complexrecruitstructural genomicstherapeutic targettumorigenesiszinc finger nuclease
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project Summary Abstract. NUT midline carcinoma (NMC), with a median survival of 6.7 months, is one of
the most aggressive solid tumors known. It is a subtype of squamous cell carcinoma characterized by
translocation of the NUT (aka NUTM1) gene, most commonly forming a fusion to the double-bromodomain
encoding protein (BET), BRD4. There is an urgent need for the identification of more specific therapeutic
targets in NMC. The over-reaching goal of this proposed project is to greater understand the mechanism of
BRD4-NUT oncogenesis and identify effective therapeutic targets for treating this disease.
BRD4-NUT functions to block differentiation and maintain proliferation of NMC cells, largely through
activation of MYC expression. This function is disrupted upon treatment with BET inhibitors, which as acetyl-
lysine mimetics prevent binding of BRD4 bromodomains to acetylated chromatin. BRD4-NUT drives the
expression of pro-growth target genes, including MYC, through the formation of megabase-sized massive
hyperacetylated 'megadomains'. BRD4-NUT megadomains arise from pre-existing active enhancers and
spread to fill cell-type-specific topologically associating domains (TADs). TADs are higher order genomic
structures whose function is to orchestrate cell-fate determining transcriptional programs through DNA-DNA
contacts. Unique proteins recruited by BRD4-NUT recently identified by our group include the histone acetyl-
transferase (HAT), p300, and several ZNF proteins collectively termed Z4. These findings indicate that BRD4-
NUT ‘hijacks’ cell-type specific TADs to drive transcription of pro-growth, anti-differentiative genes as
postulated in the following model: First, BRD4-NUT complex proteins seed regions corresponding to cell-type-
specific active TADs through the chromatin-binding of BRD4. Second, megadomains form from contiguous
expansion of BRD4-NUT complexes across chromatin in a feed-forward manner dependent upon p300 HAT
activity. Third, megadomain size is limited by TAD boundaries and HDAC activity recruited by the Z4 complex.
Fourth, hyperacetylated chromatin, recruitment of chromatin remodelers, and upregulation of cis lncRNAs
changes the chromatin configuration to enhance DNA-DNA interactions to drive transcription of key pro-
growth, anti-differentiative genes. The goals of this proposal are to test this hypothetical model, as listed in the
specific aims below.
Aim 1. To determine how BRD4-NUT megadomains form.
Aim 2. To determine how BRD4-NUT megadomains function.
Impact. Successful completion of the aims is expected to identify key BRD4-NUT-associated proteins in
pathologic megadomain formation, and will identify novel and possibly more effective therapeutic targets in
NMC and other cancers. In addition, we predict that BRD4-NUT megadomains will provide a model with far-
reaching impact on the structure-function relationship of chromatin conformation in cancer and development.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Genetically engineered mouse model to improve therapy of NUT carcinoma
-
批准号:10773306
-
项目类别:
-
资助金额:$67.25万
-
财政年份:2023
-
负责人:Christopher A French
-
依托单位:
IQGAP1 in microbial pathogenesis
-
批准号:7898607
-
项目类别:
-
资助金额:$44.5万
-
财政年份:2009
-
负责人:Christopher A French
-
依托单位:
Pathogenesis of NUT-Rearranged Carcinoma
-
批准号:7840409
-
项目类别:
-
资助金额:$29.93万
-
财政年份:2007
-
负责人:Christopher A French
-
依托单位:
Pathogenesis and Treatment of NUT-Midline Carcinoma
-
批准号:9052720
-
项目类别:
-
资助金额:$36.68万
-
财政年份:2007
-
负责人:Christopher A French
-
依托单位:
Pathogenesis and Treatment of NUT-Midline Carcinoma
-
批准号:10152520
-
项目类别:
-
资助金额:$34.01万
-
财政年份:2007
-
负责人:Christopher A French
-
依托单位:
Pathogenesis of NUT-Rearranged Carcinoma
-
批准号:7177980
-
项目类别:
-
资助金额:$29.93万
-
财政年份:2007
-
负责人:Christopher A French
-
依托单位:
Pathogenesis of NUT-Rearranged Carcinoma
-
批准号:8071200
-
项目类别:
-
资助金额:$29.03万
-
财政年份:2007
-
负责人:Christopher A French
-
依托单位:
Pathogenesis and Treatment of NUT-Midline Carcinoma
-
批准号:8579312
-
项目类别:
-
资助金额:$29.26万
-
财政年份:2007
-
负责人:Christopher A French
-
依托单位:
Pathogenesis and Treatment of NUT midline carcinoma
-
批准号:10655930
-
项目类别:
-
资助金额:$42.2万
-
财政年份:2007
-
负责人:Christopher A French
-
依托单位:
Pathogenesis of NUT-Rearranged Carcinoma
-
批准号:7491241
-
项目类别:
-
资助金额:$29.93万
-
财政年份:2007
-
负责人:Christopher A French
-
依托单位:
Pathogenesis and Treatment of NUT-Midline Carcinoma
-
批准号:10407464
-
项目类别:
-
资助金额:$33.33万
-
财政年份:2007
-
负责人:Christopher A French
-
依托单位:
Pathogenesis and Treatment of NUT-Midline Carcinoma
-
批准号:8689968
-
项目类别:
-
资助金额:$28.42万
-
财政年份:2007
-
负责人:Christopher A French
-
依托单位:
Pathogenesis and Treatment of NUT-Midline Carcinoma
-
批准号:8839958
-
项目类别:
-
资助金额:$3.73万
-
财政年份:2007
-
负责人:Christopher A French
-
依托单位:
Pathogenesis of NUT-Rearranged Carcinoma
-
批准号:7622697
-
项目类别:
-
资助金额:$29.93万
-
财政年份:2007
-
负责人:Christopher A French
-
依托单位:
Pathogenesis of NUT-Rearranged Carcinoma
-
批准号:8073242
-
项目类别:
-
资助金额:$1.17万
-
财政年份:2007
-
负责人:Christopher A French
-
依托单位:
T(15;19) in Aggressive Pediatric Carcinoma
-
批准号:7094212
-
项目类别:
-
资助金额:$13.93万
-
财政年份:2002
-
负责人:Christopher A French
-
依托单位:
T(15;19) in Aggressive Pediatric Carcinoma
-
批准号:6934570
-
项目类别:
-
资助金额:$13.93万
-
财政年份:2002
-
负责人:Christopher A French
-
依托单位:
T(15;19) in Aggressive Pediatric Carcinoma
-
批准号:6478021
-
项目类别:
-
资助金额:$13.93万
-
财政年份:2002
-
负责人:Christopher A French
-
依托单位:
T(15;19) in Aggressive Pediatric Carcinoma
-
批准号:6750635
-
项目类别:
-
资助金额:$13.93万
-
财政年份:2002
-
负责人:Christopher A French
-
依托单位:
T(15;19) in Aggressive Pediatric Carcinoma
-
批准号:6607404
-
项目类别:
-
资助金额:$13.93万
-
财政年份:2002
-
负责人:Christopher A French
-
依托单位:
国内基金
海外基金
登录
查看更多内容
BET-Bromodomain小分子抑制剂和BET蛋白降解剂的设计合成及其表观遗传学性质研究
-
批准号:81673295
-
项目类别:面上项目
-
资助金额:59.0万元
-
批准年份:2016
-
负责人:赵玉军
-
依托单位:
新型BET Bromodomain抑制剂治疗多发性硬化炎症反应的机制研究
-
批准号:81601409
-
项目类别:青年科学基金项目
-
资助金额:17.5万元
-
批准年份:2016
-
负责人:赵黎
-
依托单位:
基于片段的新型BET Bromodomain小分子抑制剂的设计、合成与生物活性研究
-
批准号:81473077
-
项目类别:面上项目
-
资助金额:70.0万元
-
批准年份:2014
-
负责人:陈亚东
-
依托单位:
新型琥珀酰化、肉豆蔻酰化转移酶及其Bromodomain的发现
-
批准号:21302027
-
项目类别:青年科学基金项目
-
资助金额:25.0万元
-
批准年份:2013
-
负责人:何彬
-
依托单位:
基于PCAF Bromodomain三维结构的抗艾滋病药物的设计与合成
-
批准号:30572234
-
项目类别:面上项目
-
资助金额:31.0万元
-
批准年份:2005
-
负责人:汪志勇
-
依托单位:
酿酒酵母含Bromodomain转录因子Bdf1p在高盐胁迫反应中调控机制的研究
-
批准号:30570031
-
项目类别:面上项目
-
资助金额:26.0万元
-
批准年份:2005
-
负责人:鲍晓明
-
依托单位:
新bromodomain基因BRD7参与鼻咽癌细胞周期调控的机制研究
-
批准号:30400238
-
项目类别:青年科学基金项目
-
资助金额:24.0万元
-
批准年份:2004
-
负责人:周洁
-
依托单位:
一个新的bromodomain基因的功能研究
-
批准号:30200135
-
项目类别:青年科学基金项目
-
资助金额:25.0万元
-
批准年份:2002
-
负责人:张小慧
-
依托单位: